424 related articles for article (PubMed ID: 20182025)
61. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.
Tiepolt S; Patt M; Hoffmann KT; Schroeter ML; Sabri O; Barthel H
J Alzheimers Dis; 2015; 47(3):539-43. PubMed ID: 26401690
[TBL] [Abstract][Full Text] [Related]
62. Alzheimer's disease: genetic basis and amyloid imaging as endophenotype.
Berti V; Nacmias B; Bagnoli S; Sorbi S
Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):225-36. PubMed ID: 21532537
[TBL] [Abstract][Full Text] [Related]
63. Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention.
Vanitallie TB
Metabolism; 2013 Jan; 62 Suppl 1():S30-3. PubMed ID: 23021038
[TBL] [Abstract][Full Text] [Related]
64. Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments.
Reiman EM;
Neurobiol Aging; 2011 Dec; 32 Suppl 1(Suppl 1):S44-7. PubMed ID: 21983241
[TBL] [Abstract][Full Text] [Related]
65. AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention.
Meyer PF; McSweeney M; Gonneaud J; Villeneuve S
Prog Mol Biol Transl Sci; 2019; 165():63-106. PubMed ID: 31481172
[TBL] [Abstract][Full Text] [Related]
66. Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment.
Dimou E; Booij J; Rodrigues M; Prosch H; Attems J; Knoll P; Zajicek B; Dudczak R; Mostbeck G; Kuntner C; Langer O; Bruecke T; Mirzaei S
Curr Alzheimer Res; 2009 Jun; 6(3):312-9. PubMed ID: 19519314
[TBL] [Abstract][Full Text] [Related]
67. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition.
Meier SR; Syvänen S; Hultqvist G; Fang XT; Roshanbin S; Lannfelt L; Neumann U; Sehlin D
J Nucl Med; 2018 Dec; 59(12):1885-1891. PubMed ID: 29853653
[TBL] [Abstract][Full Text] [Related]
68. Statistical Voxel-Based Methods and [18F]FDG PET Brain Imaging: Frontiers for the Diagnosis of AD.
Gallivanone F; Della Rosa PA; Castiglioni I
Curr Alzheimer Res; 2016; 13(6):682-94. PubMed ID: 26567733
[TBL] [Abstract][Full Text] [Related]
69. Subthreshold Amyloid Predicts Tau Deposition in Aging.
Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
[TBL] [Abstract][Full Text] [Related]
70. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.
Toyama H; Ye D; Ichise M; Liow JS; Cai L; Jacobowitz D; Musachio JL; Hong J; Crescenzo M; Tipre D; Lu JQ; Zoghbi S; Vines DC; Seidel J; Katada K; Green MV; Pike VW; Cohen RM; Innis RB
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):593-600. PubMed ID: 15791432
[TBL] [Abstract][Full Text] [Related]
71. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.
Drzezga A; Altomare D; Festari C; Arbizu J; Orini S; Herholz K; Nestor P; Agosta F; Bouwman F; Nobili F; Walker Z; Frisoni GB; Boccardi M;
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1487-1496. PubMed ID: 29756163
[TBL] [Abstract][Full Text] [Related]
72. Fluorine-18-Labeled Diaryl-azines as Improved β-Amyloid Imaging Tracers: From Bench to First-in-Human Studies.
Li Y; Zhou K; Zhang X; Zhao H; Wang X; Dong R; Wang Y; Chen B; Yan XX; Dai J; Sui Y; Zhang J; Cui M
J Med Chem; 2023 Apr; 66(7):4603-4616. PubMed ID: 36932961
[TBL] [Abstract][Full Text] [Related]
73. Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer's disease.
Ortner M; Drost R; Hedderich D; Goldhardt O; Müller-Sarnowski F; Diehl-Schmid J; Förstl H; Yakushev I; Grimmer T
BMC Neurol; 2019 Oct; 19(1):264. PubMed ID: 31672138
[TBL] [Abstract][Full Text] [Related]
74. Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease.
Liguori C; Chiaravalloti A; Nuccetelli M; Izzi F; Sancesario G; Cimini A; Bernardini S; Schillaci O; Mercuri NB; Fabio P
J Neurol; 2017 Nov; 264(11):2215-2223. PubMed ID: 28900724
[TBL] [Abstract][Full Text] [Related]
75. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
76. Validation of a New Imaging Technique Using the Glucose Metabolism to Amyloid Deposition Ratio in the Diagnosis of Alzheimer's Disease.
Takahashi R; Ishii K; Yokoyama K; For The Alzheimer S Disease Neuroimaging Initiative EY
Curr Alzheimer Res; 2017; 14(2):161-168. PubMed ID: 27334941
[TBL] [Abstract][Full Text] [Related]
77. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease.
Kawachi T; Ishii K; Sakamoto S; Sasaki M; Mori T; Yamashita F; Matsuda H; Mori E
Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):801-9. PubMed ID: 16550383
[TBL] [Abstract][Full Text] [Related]
78. Positron emission tomography imaging in dementia.
Herholz K; Carter SF; Jones M
Br J Radiol; 2007 Dec; 80 Spec No 2():S160-7. PubMed ID: 18445746
[TBL] [Abstract][Full Text] [Related]
79. PET amyloid-beta imaging in preclinical Alzheimer's disease.
Vlassenko AG; Benzinger TL; Morris JC
Biochim Biophys Acta; 2012 Mar; 1822(3):370-9. PubMed ID: 22108203
[TBL] [Abstract][Full Text] [Related]
80. The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology.
Aghakhanyan G; Vergallo A; Gennaro M; Mazzarri S; Guidoccio F; Radicchi C; Ceravolo R; Tognoni G; Bonuccelli U; Volterrani D
Neurodegener Dis; 2018; 18(5-6):302-309. PubMed ID: 30814473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
